Skip To Main Content
Ying Tam on Muck Rack

Ying Tam

As seen in: Nature, Science Magazine, Cell Press, The Scientist, Smart Cities Dive, The Medicine Maker
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ying

Contact Ying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

In Vivo CAR T: A New Route to Treating Autoimmune Disease

|
By Ying Tam, Sean Semple
| The Medicine Maker Verified
To date, the remarkable effectiveness of chimeric antigen receptor (CAR) T-cell therapy has been largely limited to hematologic malignancies. Blood cancer patients facing a terminal diagnosis are often willing to undergo a burdensome treatment regimen and tolerate significant side effects in exchange for a chance at long-term remission.
Open in Who Shared Issue with article?

Enhanced B cell priming induces broadly neutralizing HIV-1 apex antibodies

|
By Lorie Marchitto, Kshitij Wagh, Ryan Roark, Séverin Coléon, Hui Li, Ashwin N. Skelly, Michael P. Hogarty, Rumi Habib, Wenge Ding, Kasirajan Ayyanathan, Weimin Liu, Zizhang Sheng, Yicheng Guo, Lena Smith, Laura Sutherland, Younghoon Park, Andrew Connell, Frederic Bibollet-Ruche, Emily Lewis, Samantha Plante, Macy J. Akeley, Chengyan Zhao, John Carey, Christian Martella, Yingying Li, Mary S. Campion, Rebecca A. Osbaldeston, Colette G. Gordon, Amie Albertus, Justin Su, Chiaki Noguchi, Ying Tam, Christopher Barbosa, Xuduo Li, Agnes Walsh, Darrell J. Irvine, Raiees Andrabi, Robert Edwards, Edward F. Kreider, Drew Weissman, Lawrence Shapiro, Peter D. Kwong, Bette Korber, Barton F. Haynes, Kevin Saunders, Beatrice H. Hahn, George Shaw, Joena Bal, Jinery Lora, Melinda G. Lituchy, Khaled Amereh
| Nature Verified
Abstract Efficient priming of B cell precursors is a rate-limiting step in the induction of V2 apex broadly neutralizing antibodies (bNAbs)1,2. Here, we describe a novel germline-targeted HIV-1 Env (CAP256.OPT4) that increases the efficiency of V2 apex bNAb precursor priming by 30-400 fold compared with wild-type HIV-1 Envs and induces – in >90% of macaques – neutralization breadth that includes N130-containing viruses.
Open in Who Shared Issue with article?

Cargo-free LNP Manufacturing Could Spark a Nucleic Acid Therapy Renaissance

|
By Ying Tam, Paulo J. C. Lin
| The Scientist Verified
The Elegance of Nucleic Acid Therapy is Compromised by Logistic Complexity Conventional biologics are static; their structure and mechanism are fixed once they are developed. In contrast, nucleic acid therapies are inherently programmable—putting treatments once thought to be impossible within reach.
Open in Who Shared Issue with article?
See all 16 articles